2,4-Dihydroxybenzaldehyde

2,4-Dihydroxybenzaldehyde is an endogenous metabolite. 2,4-Dihydroxybenzaldehyde is a pharmaceutical intermediate that can be used to synthesize various Schiff base compounds. 2,4-Dihydroxybenzaldehyde exhibits significant anti angiogenic, anti-inflammatory, and analgesic activities. 2,4-Dihydroxybenzaldehyde reduces the production of NO and ROS by inhibiting the expression of iNOS and COX-2. 2,4-Dihydroxybenzaldehyde is commonly used in the study of inflammatory conditions^[1][2]. In Vitro:2,4-Dihydroxybenzaldehyde (0-0.1 mM, 24 h) significantly inhibits LPS (HY-D1056) induced NO production in a dose-dependent manner in RAW264.7 cells^[2].
2,4-Dihydroxybenzaldehyde (0-0.1 mM, 24 h) inhibits LPS induced iNOS and COX-2 protein expression in a dose-dependent manner in RAW264.7 cells^[2].
2,4-Dihydroxybenzaldehyde (0-0.05 mM, 24 h) can slightly reduce the increase in ROS levels caused by LPS in RAW264.7 cells^[2].
2,4-Dihydroxybenzaldehyde (0-0.1 mM, 24 h) is non-toxic to RAW264.7 cells^[2]. In Vivo:2,4-Dihydroxybenzaldehyde (10-100 mg/kg, p.o., single dose) inhibits the increase of vascular permeability and exhibits analgesic activity in a dose-dependent manner in male ICR mice induced by acetic acid (HY-Y0319)^[2].
2,4-Dihydroxybenzaldehyde (0.03-0.3 mg/pouch, directly inject the airbag, single dose) significantly reduces exudate volume, neutrophil count, and nitrite content in rats with a λ-carrageenan (HY-N9470)-induced air pouch formation^[2].